NasdaqCM:CLRB

Stock Analysis Report

Executive Summary

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Risks

  • Cellectar Biosciences has significant price volatility in the past 3 months.

Share Price & News

How has Cellectar Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.9%

NasdaqCM:CLRB

0.2%

US Biotechs

0.2%

US Market


1 Year Return

-21.7%

NasdaqCM:CLRB

-9.1%

US Biotechs

-0.7%

US Market

CLRB underperformed the Biotechs industry which returned -7.3% over the past year.

CLRB underperformed the Market in United States of America which returned 0.3% over the past year.


Share holder returns

CLRBIndustryMarket
7 Day0.9%0.2%0.2%
30 Day0%0.9%-2.7%
90 Day7.0%2.4%1.6%
1 Year-21.7%-21.7%-8.4%-9.1%1.6%-0.7%
3 Year-91.7%-91.7%8.3%4.6%40.0%30.9%
5 Year-99.3%-99.3%4.5%-0.3%53.8%36.8%

Price Volatility Vs. Market

How volatile is Cellectar Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cellectar Biosciences undervalued based on future cash flows and its price relative to the stock market?

1.35x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Cellectar Biosciences to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Cellectar Biosciences to establish if it is available at substantial discount.


Price Based on Earnings

Cellectar Biosciences is loss making, we can't compare its value to the US Biotechs industry average.

Cellectar Biosciences is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Cellectar Biosciences, we can't assess if its growth is good value.


Price Based on Value of Assets

Cellectar Biosciences is good value based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Cellectar Biosciences expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

-7.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Cellectar Biosciences is high growth as no revenue estimate data is available.

Cellectar Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare Cellectar Biosciences's revenue growth to the United States of America market average as no estimate data is available.

Unable to compare Cellectar Biosciences's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Cellectar Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Cellectar Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Cellectar Biosciences performed over the past 5 years?

-20.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Cellectar Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Cellectar Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Cellectar Biosciences's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Cellectar Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Cellectar Biosciences has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Cellectar Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Cellectar Biosciences's financial position?


Financial Position Analysis

Cellectar Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Cellectar Biosciences's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Cellectar Biosciences has no debt.

Cellectar Biosciences currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Cellectar Biosciences has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Cellectar Biosciences has sufficient cash runway for 1.5 years based on current free cash flow.

Cellectar Biosciences has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 14.1% each year.


Next Steps

Dividend

What is Cellectar Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Cellectar Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Cellectar Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Cellectar Biosciences has not reported any payouts.

Unable to verify if Cellectar Biosciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Cellectar Biosciences has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Cellectar Biosciences's salary, the management and board of directors tenure and is there insider trading?

1.9yrs

Average management tenure


CEO

Jim Caruso (60yo)

4.2yrs

Tenure

US$770,012

Compensation

Mr. James V. Caruso, also known as Jim, has been the Chief Executive Officer and President of Cellectar Biosciences, Inc. since June 15, 2015. Mr. Caruso served as the Chief Commercial Officer and Executiv ...


CEO Compensation Analysis

Jim's remuneration is higher than average for companies of similar size in United States of America.

Jim's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.9yrs

Average Tenure

58yo

Average Age

The average tenure for the Cellectar Biosciences management team is less than 2 years, this suggests a new team.


Board Age and Tenure

4.2yrs

Average Tenure

60.5yo

Average Age

The tenure for the Cellectar Biosciences board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$20001 Mar 19
Jarrod Longcor
EntityIndividual
Role
Senior Key Executive
Chief Business Officer
Shares100
Max PriceUS$2.00
BuyUS$2,28230 Nov 18
James Caruso
EntityIndividual
Role
Chief Executive Officer
President
Shares1,000
Max PriceUS$2.28
SellUS$2,19230 Nov 18
Stephen Hill
EntityIndividual
Role
Member of the Board of Directors
Director
Shares992
Max PriceUS$2.21

Ownership Breakdown


Management Team

  • Jim Caruso (60yo)

    President

    • Tenure: 4.2yrs
    • Compensation: US$770.01k
  • Jarrod Longcor (46yo)

    Chief Business Officer

    • Tenure: 1.9yrs
    • Compensation: US$477.89k
  • Chip Bernhardt (58yo)

    Interim Chief Financial Officer

    • Tenure: 0.4yrs
  • Gregory Lynch

    Secretary

    • Tenure: 0.0yrs

Board Members

  • John Neis (64yo)

    Director

    • Tenure: 11.5yrs
    • Compensation: US$72.18k
  • Stephen Hill (61yo)

    Director

    • Tenure: 12.6yrs
    • Compensation: US$72.18k
  • Fred Driscoll (68yo)

    Director

    • Tenure: 2.3yrs
    • Compensation: US$72.18k
  • Jim Caruso (60yo)

    President

    • Tenure: 4.2yrs
    • Compensation: US$770.01k
  • Stefan Loren (55yo)

    Independent Director

    • Tenure: 4.2yrs
    • Compensation: US$72.18k
  • Doug Swirsky (50yo)

    Chairman of the Board

    • Tenure: 2.0yrs
    • Compensation: US$72.18k

Company Information

Cellectar Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cellectar Biosciences, Inc.
  • Ticker: CLRB
  • Exchange: NasdaqCM
  • Founded: 2002
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$20.014m
  • Shares outstanding: 9.40m
  • Website: https://www.cellectar.com

Number of Employees


Location

  • Cellectar Biosciences, Inc.
  • 100 Campus Drive
  • Florham Park
  • New Jersey
  • 7932
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CLRBNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 2011
NV4PDB (Deutsche Boerse AG)YesCommon StockDEEURMar 2011

Biography

Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjug ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/21 00:10
End of Day Share Price2019/08/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.